[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362263-105":59,"doc-detail-362263-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-landscape-of-advanced-endometrial-cancer-exploratory-analyses-at-modena-cancer-center-memo","Molecular Landscape of Advanced Endometrial Cancer - Exploratory Analyses at Modena Cancer Center (MEMO)","","Despite the introduction of novel therapeutic options, the prognosis of advanced endometrial cancer remains poor. This single-center retrospective exploratory study analyzes 32 patients with advanced or recurrent disease treated at the Modena Cancer Center. DNA mutations, copy number variations, and RNA expression were profiled to map the molecular landscape, compare alterations across predefined clinical subgroups, and assess associations with overall survival. PTEN and PIK3CA mutations were prevalent, CTNNB1 related to favorable outcome, while KRAS correlated with poorer survival. Results indicate the need for further work on therapeutic implications and combinatorial strategies targeting specific alterations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-landscape-of-advanced-endometrial-cancer-exploratory-analyses-at-modena-cancer-center-memo/362263/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-landscape-of-advanced-endometrial-cancer-exploratory-analyses-at-modena-cancer-center-memo/362263.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What study population and design were used for the molecular profiling of advanced endometrial cancer?","Question",{"text":112,"@type":113},"The study is a single-center, retrospective, exploratory analysis of 32 patients with advanced or recurrent endometrial cancer treated at the Modena Cancer Center.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which molecular data types were analyzed, and what was the main objective?",{"text":117,"@type":113},"DNA mutations, copy number variations, and RNA expression were assessed. The goal was to characterize the molecular landscape, examine alterations across clinical subgroups, and evaluate links to overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"How did specific mutations relate to prognosis in this cohort?",{"text":121,"@type":113},"CTNNB1 mutations were associated with a favorable prognostic impact, whereas KRAS mutations correlated with poorer overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362263,1790451433,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Article  \nMolecular Landscape of Advanced Endometrial Cancer:  \nExploratory Analyses at Modena Cancer Center (MEMO)  \nMarta Pirola 1,†, Eleonora Molinaro 2,†, Samantha Manfredini 3, Riccardo Cuoghi Costantini 4, Chiara Carlucci 1, Claudia Piombino 5, Stefania Pipitone 5, Maria Giuseppa Vitale 5, Roberto Sabbatini 5, Francesca Bacchelli 6, Laura Botticelli 7, Albino Eccher 7, Roberto D’Amico 4, Lucia Longo 2, Stefania Bettelli 3, Cinzia Baldessari 5, *,‡ and Massimo Dominici 1,5,‡  \nAcademic Editors: Yung-Taek Ouhand Georgios Valsamakis  \nReceived: 11 November 2025  \nRevised: 11 January 2026  \nAccepted: 14 January 2026  \nPublished: 22 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy;  \n[marta.pirola04@gmail.com](marta.pirola04@gmail.com) (M.P.); [325498@studenti.unimore.it](325498@studenti.unimore.it) (C.C.); [mdominici@unimore.it](mdominici@unimore.it) (M.D.)  \n2 Oncology Area Sud AUSL Modena, Ospedale of Sassuolo, 41049 Sassuolo, Italy; [e.molinaro@ausl.mo.it](e.molinaro@ausl.mo.it) (E.M.); [l.longo@ausl.mo.it](l.longo@ausl.mo.it) (L.L.)  \n3 Division of Molecular Pathology and Predictive Medicine, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy; [manfredini.samantha@aou.mo.it](manfredini.samantha@aou.mo.it) (S.M.); [bettelli.stefania@aou.mo.it](bettelli.stefania@aou.mo.it) (S.B.)  \n4 Statistics Unit, Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and  \nReggio Emilia, 41124 Modena, Italy; [337988@studenti.unimore.it](337988@studenti.unimore.it) (R.C.C.); [roberto.damico@unimore.it](roberto.damico@unimore.it) (R.D.)  \n5 Division of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy; [claudia.piombino@outlook.com](claudia.piombino@outlook.com) (C.P.); [pipitone.stefania@aou.mo.it](pipitone.stefania@aou.mo.it) (S.P.); [vitale.mariagiuseppa@aou.mo.it](vitale.mariagiuseppa@aou.mo.it) (M.G.V.); [sabbrob@unimore.it](sabbrob@unimore.it) (R.S.)  \n6 Clinical Trials Office, Division of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy; [francesca.bacchelli@unimore.it](francesca.bacchelli@unimore.it)  \n7 Department of Pathology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy; [botticelli.laura@aou.mo.it](botticelli.laura@aou.mo.it) (L.B.); [eccher.albino@aou.mo.it](eccher.albino@aou.mo.it) (A.E.)  \n* [Correspondence: baldessari.cinzia@aou.mo.it](Correspondence: baldessari.cinzia@aou.mo.it)[ ](Correspondence: baldessari.cinzia@aou.mo.it)† These authors contributed equally to this study.  \n‡ These authors also contributed equally to this study.  \nAbstract  \nDespite the introduction of novel therapeutic options, the prognosis of advanced endometrial cancer remains poor. In recent years, increasing attention has been directed toward the molecular characterization of endometrial cancer. However, data specifically focusing on advanced-stage disease are still limited. In our single-center, retrospective, exploratory study with a limited sample size, we analyzed 32 patients with advanced or recurrent endometrial cancer treated at the Modena Cancer Center. Comprehensive molecular profiling was performed to assess DNA mutations, copy number variations, and RNA expression. We characterized the molecular landscape of this cohort, evaluated selected genomic alterations across predefined clinical subgroups, and explored their association with overall survival. Consistent with previous reports, a high prevalence of PTEN and PIK3CA mutations were observed. Patients experiencing relapse more than six months after diagnosis were more likely to harbor CTNNB1 mutations. KRAS mutations were more frequently detected in younger patients and in those with en","cbCaiu8h9T7pLvwc","https://ap.wps.com/l/cbCaiu8h9T7pLvwc","pdf",1752518,21,"English","# Introduction\n## General Characteristics of Endometrial Cancer\n# Materials and Methods\n## Patient cohort and treatment context\n## Molecular profiling strategy\n# Results\n## Molecular landscape and mutation prevalence\n## Alterations by clinical subgroups\n## Associations with overall survival\n# Discussion\n## Prognostic implications and therapeutic considerations\n# Conclusions\n## Future directions","[{\"question\":\"What study population and design were used for the molecular profiling of advanced endometrial cancer?\",\"answer\":\"The study is a single-center, retrospective, exploratory analysis of 32 patients with advanced or recurrent endometrial cancer treated at the Modena Cancer Center.\"},{\"question\":\"Which molecular data types were analyzed, and what was the main objective?\",\"answer\":\"DNA mutations, copy number variations, and RNA expression were assessed. The goal was to characterize the molecular landscape, examine alterations across clinical subgroups, and evaluate links to overall survival.\"},{\"question\":\"How did specific mutations relate to prognosis in this cohort?\",\"answer\":\"CTNNB1 mutations were associated with a favorable prognostic impact, whereas KRAS mutations correlated with poorer overall survival.\"}]","Molecular Landscape of Advanced Endometrial Cancer - Exploratory Analyses at Modena Cancer Center (MEMO) | PDF",1790146915,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7222fb40910d54d138f669319b6d9f66.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db4458ac8c6d85fd9c1bc5206456e62a.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fd82f6eedc23485bd65e3b4776cecc9.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2d765ab4b92c1af7c638a6f166c5efc.webp",980,1385]